CGAMP

• Description :

  CGAMP (Cyclic GMP-AMP) functions as an endogenous second messenger in metazoans and triggers interferon production in response to cytosolic DNA. cGAMP activates stimulator of interferon genes (STING), which activates a signaling cascade leading to the production of type I interferons and other immune mediators[1][2][3][4].

• Product Name Alternative :

  Cyclic GMP-AMP; 3',3'-cGAMP

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  STING

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/cGAMP.html

• Purity :

  99.22

• Solubility :

  H2O : 180 mg/mL (ultrasonic)

• Smiles :

  O=P(O[C@H]1[C@@H](O)[C@H](N2C=NC3=C2N=CN=C3N)O[C@@H]1COP4(O)=O)(O)OC[C@@H]5[C@@H](O4)[C@@H](O)[C@H](N6C=NC7=C6N=C(N)NC7=O)O5

• Molecular Formula :

  C20H24N10O13P2

• Molecular Weight :

  674.41

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Wu J, et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science. 2013 Feb 15;339 (6121) :826-30.|[2]Skrnjug I, et al. Cyclic GMP-AMP displays mucosal adjuvant activity in mice. PLoS One. 2014 Oct 8;9 (10) :e110150.|[3]Liu Y, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med. 2014 Aug 7;371 (6) :507-18.|[4]Ablasser A, et al. Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP. Nature. 2013 Nov 28;503 (7477) :530-4.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Citation 01 :

  ACS Nano. 2025 Mar 4;19 (8) :8277-8293.|Adv Sci (Weinh) . 2025 Mar 26:e2502750.|Biochem Pharmacol. 2023 Jul:213:115618.|Biomaterials. 2023 Jun:297:122104.|Cancer Immunol Res. 2025 Nov 11.|Cell Death Differ. 2025 Jun;32 (6) :1167-1179.|Cell Rep. 2023 Apr 5;42 (4) :112328.|Chem Eng J. 2022: 140190.|Chin Herb Med. 2024 Apr 30;16 (3) :422-434.|J Nanobiotechnology. 2022 Jan 6;20 (1) :23.|Nat Commun. 2024 Dec 4;15 (1) :10543.|Nat Commun. 2024 Jul 18;15 (1) :6053.|Nat Commun. 2024 Jul 23;15 (1) :6193.|Nat Commun. 2025 May 23;16 (1) :4793.|Sci China Life Sci. 2024 Dec;67 (12) :2664-2677.|Signal Transduct Target Ther. 2025 Oct 1;10 (1) :321.|bioRxiv. 2020 Jul.|Int Immunopharmacol. 2025 Aug 6:164:115310.|Patent. US20210017607A1.

• CAS Number :

  [849214-04-6]